Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria

American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
G JerumsC Tsalamandris

Abstract

The aim of this study is to compare the efficacy of an angiotensin-converting enzyme inhibitor with a dihydropyridine calcium channel blocker in preventing progression to macroalbuminuria and/or a decline in renal function in normotensive patients with type 1 diabetes and microalbuminuria. Forty-two patients were randomized to treatment with either perindopril, slow-release nifedipine, or placebo. In the first 3 months, drug dosage was titrated to achieve a decrease in diastolic blood pressure of at least 5 mm HG: Thirty-three patients had a minimum of 24 months' data, and 25 patients were followed up beyond 36 months (mean, 67 +/- 4 months). Patients were studied every 3 months and at the end of the treatment period; those who remained normotensive discontinued therapy and were followed up for an additional 3 months. Baseline geometric mean albumin excretion rates (AERs) were as follows: perindopril, 66 microg/min; nifedipine, 59 microg/min; and placebo, 66 microg/min. During the first 3 years, 7 of the perindopril-treated but none of the placebo or nifedipine-treated patients reverted to normoalbuminuria (P < 0.01). Median AERs at 3 years of treatment in each group were 23 microg/min for perindopril, 122 microg/min for nifedi...Continue Reading

References

Apr 1, 1992·Kidney International·S AndersonB M Brenner
Mar 16, 1991·BMJ : British Medical Journal·P PassaJ Menard
Feb 1, 1971·Australian and New Zealand Journal of Medicine·F MendelsohnC I Johnston
Nov 1, 1972·Scandinavian Journal of Clinical and Laboratory Investigation·J Bröchner-Mortensen

❮ Previous
Next ❯

Citations

May 31, 2007·The Canadian Journal of Cardiology·Philip A McFarlaneBruce Culleton
Oct 15, 2009·Diabetology & Metabolic Syndrome·Themis ZelmanovitzLuís H Canani
Sep 3, 2004·Current Hypertension Reports·Markus LassilaKarin Jandeleit-Dahm
Sep 2, 2003·Current Hypertension Reports·Douglas A Nigbor, Julia B Lewis
Jun 26, 2010·Cardiovascular Drugs and Therapy·Roberto FerrariClaudio Ceconi
May 16, 2014·Canadian Journal of Diabetes·Philip McFarlanePeter Senior
May 11, 2005·Kidney International·Merlin C ThomasUNKNOWN MDNSG Study Group
Mar 1, 2012·Journal of Renal Care·C J Hill, D G Fogarty
Jan 31, 2008·Acta Clinica Belgica·B F Schrijvers, A S De Vriese
Jan 31, 2006·Diabetes Care·Merlin C ThomasPer-Henrik Groop
Jul 15, 2016·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Nicolás R RoblesGuido Grassi
Mar 5, 2011·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Ausilia MaioneGiovanni F M Strippoli
Apr 22, 2008·São Paulo Medical Journal = Revista Paulista De Medicina·Marcelo Montebello LemosRicardo Sesso
Oct 2, 2007·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Michel Marre, Abdoulaye Leye
Apr 20, 2004·Current Opinion in Nephrology and Hypertension·Richard J MacIsaacMark E Cooper
Oct 23, 2004·Diabetic Medicine : a Journal of the British Diabetic Association·G JerumsUNKNOWN Melbourne Diabetic Nephropathy Study Group
Mar 20, 2003·Current Diabetes Reports·D Martins, K Norris
Feb 23, 2005·Expert Review of Cardiovascular Therapy·Roberto Ferrari
Jun 3, 2005·Journal of the American Society of Nephrology : JASN·Josephine M ForbesMark E Cooper
Oct 10, 2008·Journal of the American Society of Nephrology : JASN·Andrew M LuksErik R Swenson
Nov 13, 2009·American Journal of Physiology. Renal Physiology·Ilaria MiceliGabriella Gruden
Apr 17, 2003·Current Opinion in Nephrology and Hypertension·Sheldon Tobe
Feb 19, 2020·Expert Opinion on Pharmacotherapy·Alexandra KatsimardouVasilios G Athyros
Jun 26, 2003·Journal of Internal Medicine·C E Mogensen
Aug 22, 2003·Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension·Giancarlo Viberti
Feb 22, 2002·Current Opinion in Nephrology and Hypertension·Karin Jandeleit-Dahm, Mark E Cooper
Jul 23, 2003·Diabetic Medicine : a Journal of the British Diabetic Association·R E GilbertD J Kelly
Jan 7, 2004·Diabetic Medicine : a Journal of the British Diabetic Association·C E Mogensen, M E Cooper
Feb 28, 2021·Kidney International·UNKNOWN Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group
Oct 2, 2020·Kidney International·UNKNOWN Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.